{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:21:48Z","timestamp":1781112108112,"version":"3.54.1"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Polish National Science Centre","doi-asserted-by":"crossref","award":["DEC-2021\/43\/O\/NZ7\/01273"],"award-info":[{"award-number":["DEC-2021\/43\/O\/NZ7\/01273"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10620-025-08873-8","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:20:31Z","timestamp":1739992831000},"page":"1293-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of Cytochromes P450 in Intestinal Barrier Function: Possible Involvement in the Pathogenesis of Leaky Gut Syndrome"],"prefix":"10.1007","volume":"70","author":[{"given":"Adam","family":"Makaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Jaczynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikolaj","family":"Swierczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Salaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"8873_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/J.MOLIMM.2004.12.004","volume":"42","author":"R Dommett","year":"2005","unstructured":"Dommett R, Zilbauer M, George JT et al. Innate immune defence in the human gastrointestinal tract. Mol Immunol. 2005;42:903\u2013912. https:\/\/doi.org\/10.1016\/J.MOLIMM.2004.12.004.","journal-title":"Mol Immunol."},{"key":"8873_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010083","author":"P Portincasa","year":"2021","unstructured":"Portincasa P, Bonfrate L, Khalil M et al. Intestinal barrier and permeability in health, obesity and NAFLD. Biomedicines. 2021. https:\/\/doi.org\/10.3390\/biomedicines10010083.","journal-title":"Biomedicines."},{"key":"8873_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-014-0189-7","volume":"14","author":"SC Bischoff","year":"2014","unstructured":"Bischoff SC, Barbara G, Buurman W et al. Intestinal permeability\u2014a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:1\u201325. https:\/\/doi.org\/10.1186\/s12876-014-0189-7.","journal-title":"BMC Gastroenterol."},{"key":"8873_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0B013E31826AE849","author":"F Scaldaferri","year":"2012","unstructured":"Scaldaferri F, Pizzoferrato M, Gerardi V et al. The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol. 2012. https:\/\/doi.org\/10.1097\/MCG.0B013E31826AE849.","journal-title":"J Clin Gastroenterol."},{"key":"8873_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph182312836","author":"N Di Tommaso","year":"2021","unstructured":"Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal barrier in human health and disease. Int J Environ Res Public Health. 2021. https:\/\/doi.org\/10.3390\/ijerph182312836.","journal-title":"Int J Environ Res Public Health."},{"key":"8873_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2010\/823710","volume":"2010","author":"C Jung","year":"2010","unstructured":"Jung C, Hugot JP, Barreau F. Peyer\u2019s patches: the immune sensors of the intestine. Int J Inflam. 2010;2010:1\u201312. https:\/\/doi.org\/10.4061\/2010\/823710.","journal-title":"Int J Inflam."},{"key":"8873_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.673708","author":"Y Kinashi","year":"2021","unstructured":"Kinashi Y, Hase K. Partners in leaky gut syndrome: intestinal dysbiosis and autoimmunity. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/FIMMU.2021.673708.","journal-title":"Front Immunol."},{"key":"8873_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/mi.2016.128","volume":"10","author":"R Ahmad","year":"2017","unstructured":"Ahmad R, Sorrell MF, Batra SK et al. Gut permeability and mucosal inflammation: bad, good or context dependent. Mucosal Immunol. 2017;10:307\u2013317. https:\/\/doi.org\/10.1038\/mi.2016.128.","journal-title":"Mucosal Immunol."},{"key":"8873_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrm.2016.80","volume":"17","author":"C Zihni","year":"2016","unstructured":"Zihni C, Mills C, Matter K et al. Tight junctions: from simple barriers to multifunctional molecular gates. Nat Rev Mol Cell Biol. 2016;17:564\u2013580. https:\/\/doi.org\/10.1038\/nrm.2016.80.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"8873_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","volume":"50","author":"C Chelakkot","year":"2018","unstructured":"Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50:1\u20139. https:\/\/doi.org\/10.1038\/s12276-018-0126-x.","journal-title":"Exp Mol Med."},{"key":"8873_CR11","doi-asserted-by":"publisher","DOI":"10.1152\/AJPCELL.1997.273.4.C1378","author":"JR Turner","year":"1997","unstructured":"Turner JR, Rill BK, Carlson SL et al. Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol. 1997. https:\/\/doi.org\/10.1152\/AJPCELL.1997.273.4.C1378.","journal-title":"Am J Physiol."},{"key":"8873_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2019.101636","volume":"40\u201341","author":"DL Webb","year":"2019","unstructured":"Webb DL. Tests of intestinal mucosal hyperpermeability: many diseases, many biomarkers and a bright future. Best Pract Res Clin Gastroenterol. 2019;40\u201341:101636. https:\/\/doi.org\/10.1016\/j.bpg.2019.101636.","journal-title":"Best Pract Res Clin Gastroenterol."},{"key":"8873_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23063204","author":"A Twardowska","year":"2022","unstructured":"Twardowska A, Makaro A, Binienda A et al. Preventing bacterial translocation in patients with leaky gut syndrome: nutrition and pharmacological treatment options. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23063204.","journal-title":"Int J Mol Sci."},{"key":"8873_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.tips.2016.05.006","volume":"37","author":"FP Guengerich","year":"2016","unstructured":"Guengerich FP, Waterman MR, Egli M. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci. 2016;37:625\u2013640. https:\/\/doi.org\/10.1016\/j.tips.2016.05.006.","journal-title":"Trends Pharmacol Sci."},{"key":"8873_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312808","author":"M Zhao","year":"2021","unstructured":"Zhao M, Ma J, Li M et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312808.","journal-title":"Int J Mol Sci."},{"key":"8873_CR16","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/DDR.21778","volume":"82","author":"D Fanni","year":"2021","unstructured":"Fanni D, Pinna F, Gerosa C et al. Anatomical distribution and expression of CYP in humans: neuropharmacological implications. Drug Dev Res. 2021;82:628\u2013667. https:\/\/doi.org\/10.1002\/DDR.21778.","journal-title":"Drug Dev Res."},{"key":"8873_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2174\/138920009790820138","volume":"10","author":"EG Hrycay","year":"2009","unstructured":"Hrycay EG, Bandiera SM. Expression, function and regulation of mouse cytochrome P450 enzymes: comparison with human P450 enzymes. Curr Drug Metab. 2009;10:1151\u20131183. https:\/\/doi.org\/10.2174\/138920009790820138.","journal-title":"Curr Drug Metab."},{"key":"8873_CR18","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/DMD.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS et al. The human intestinal cytochrome P450 \u201cPIE.\u201d Drug Metab Dispos. 2006;34:880. https:\/\/doi.org\/10.1124\/DMD.105.008672.","journal-title":"Drug Metab Dispos."},{"key":"8873_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.prp.2013.12.010","volume":"210","author":"D Plewka","year":"2014","unstructured":"Plewka D, Plewka A, Szczepanik T et al. Expression of selected cytochrome P450 isoforms and of cooperating enzymes in colorectal tissues in selected pathological conditions. Pathol Res Pract. 2014;210:242\u2013249. https:\/\/doi.org\/10.1016\/j.prp.2013.12.010.","journal-title":"Pathol Res Pract."},{"key":"8873_CR20","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.3748\/wjg.v25.i23.2846","volume":"25","author":"A Sen","year":"2019","unstructured":"Sen A, Stark H. Role of cytochrome P450 polymorphisms and functions in development of ulcerative colitis. World J Gastroenterol. 2019;25:2846\u20132862. https:\/\/doi.org\/10.3748\/wjg.v25.i23.2846.","journal-title":"World J Gastroenterol."},{"key":"8873_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.apha.2015.03.005","volume":"74","author":"P Christmas","year":"2015","unstructured":"Christmas P. Role of cytochrome P450s in inflammation. Adv Pharmacol. 2015;74:163\u2013192. https:\/\/doi.org\/10.1016\/bs.apha.2015.03.005.","journal-title":"Adv Pharmacol."},{"key":"8873_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECOENV.2022.113805","volume":"241","author":"X Wang","year":"2022","unstructured":"Wang X, Yang F, Na L et al. Ferulic acid alleviates AFB1-induced duodenal barrier damage in rats via up-regulating tight junction proteins, down-regulating ROCK, competing CYP450 enzyme and activating GST. Ecotoxicol Environ Saf. 2022;241:113805. https:\/\/doi.org\/10.1016\/J.ECOENV.2022.113805.","journal-title":"Ecotoxicol Environ Saf."},{"key":"8873_CR23","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.freeradbiomed.2013.09.009","volume":"65","author":"MA Abdelmegeed","year":"2013","unstructured":"Abdelmegeed MA, Banerjee A, Jang S et al. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radic Biol Med. 2013;65:1238\u20131245. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.09.009.","journal-title":"Free Radic Biol Med."},{"key":"8873_CR24","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1002\/hep.30652","volume":"73","author":"YE Cho","year":"2021","unstructured":"Cho YE, Kim DK, Seo W et al. Fructose promotes leaky gut, endotoxemia, and liver fibrosis through ethanol-inducible cytochrome P450\u20132E1\u2013mediated oxidative and nitrative stress. Hepatology. 2021;73:2180\u20132195. https:\/\/doi.org\/10.1002\/hep.30652.","journal-title":"Hepatology."},{"key":"8873_CR25","doi-asserted-by":"publisher","DOI":"10.1096\/FJ.202201061RR","author":"B Zhao","year":"2022","unstructured":"Zhao B, Huang J, Lou X et al. Endothelial CYP2J2 overexpression restores the BRB via METTL3-mediated ANXA1 upregulation. FASEB J. 2022. https:\/\/doi.org\/10.1096\/FJ.202201061RR.","journal-title":"FASEB J."},{"key":"8873_CR26","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1080\/13880209.2023.2246500","volume":"61","author":"X Xu","year":"2023","unstructured":"Xu X, Sun X, Chang M et al. Gemcitabine enhances pharmacokinetic exposure of the major components of Danggui Buxue Decoction in rat via the promotion of intestinal permeability and down-regulation of CYP3A for combination treatment of non-small cell lung cancer. Pharm Biol. 2023;61:1298. https:\/\/doi.org\/10.1080\/13880209.2023.2246500.","journal-title":"Pharm Biol."},{"key":"8873_CR27","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/J.STEM.2022.08.008","volume":"29","author":"L Chen","year":"2022","unstructured":"Chen L, Jiao T, Liu W et al. Hepatic cytochrome P450 8B1 and cholic acid potentiate intestinal epithelial injury in colitis by suppressing intestinal stem cell renewal. Cell Stem Cell. 2022;29:1366. https:\/\/doi.org\/10.1016\/J.STEM.2022.08.008.","journal-title":"Cell Stem Cell."},{"key":"8873_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1124\/MOL.106.029579","volume":"71","author":"M Osanai","year":"2007","unstructured":"Osanai M, Nishikiori N, Murata M et al. Cellular retinoic acid bioavailability determines epithelial integrity: role of retinoic acid receptor \u03b1 agonists in colitis. Mol Pharmacol. 2007;71:250\u2013258. https:\/\/doi.org\/10.1124\/MOL.106.029579.","journal-title":"Mol Pharmacol."},{"key":"8873_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/mt.2014.201","volume":"23","author":"B Li","year":"2015","unstructured":"Li B, Baylink DJ, Walter MH et al. Targeted 25-hydroxyvitamin D3 1\u03b1-hydroxylase adoptive gene therapy ameliorates dss-induced colitis without causing hypercalcemia in mice. Mol Ther. 2015;23:339\u2013351. https:\/\/doi.org\/10.1038\/mt.2014.201.","journal-title":"Mol Ther."},{"key":"8873_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1034\/j.1600-0773.2000.d01-14.x","volume":"86","author":"M Spatzenegger","year":"2000","unstructured":"Spatzenegger M, Horsmans Y, Verbeeck RK. Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats. Pharmacol Toxicol. 2000;86:71\u201377. https:\/\/doi.org\/10.1034\/j.1600-0773.2000.d01-14.x.","journal-title":"Pharmacol Toxicol."},{"key":"8873_CR31","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1124\/mol.113.086637","volume":"84","author":"DW Nebert","year":"2013","unstructured":"Nebert DW, Shi Z, G\u00e1lvez-Peralta M et al. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol. 2013;84:304\u2013313. https:\/\/doi.org\/10.1124\/mol.113.086637.","journal-title":"Mol Pharmacol."},{"key":"8873_CR32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1124\/dmd.119.087718","volume":"47","author":"Y Kapelyukh","year":"2019","unstructured":"Kapelyukh Y, Henderson CJ, Scheer N et al. Defining the contribution of CYP1A1 and CYP1A2 to drug metabolism using humanized CYP1A1\/1A2 and Cyp1a1\/Cyp1a2 knockout mice. Drug Metab Dispos. 2019;47:907\u2013918. https:\/\/doi.org\/10.1124\/dmd.119.087718.","journal-title":"Drug Metab Dispos."},{"key":"8873_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121201","author":"F Klomp","year":"2020","unstructured":"Klomp F, Wenzel C, Drozdzik M et al. Drug-drug interactions involving intestinal and hepatic CYP1A enzymes. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12121201.","journal-title":"Pharmaceutics."},{"key":"8873_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1124\/JPET.117.243246\/-\/DC1","volume":"363","author":"D Lin","year":"2017","unstructured":"Lin D, Kostov R, Huang JTJ et al. Novel pathways of ponatinib disposition catalyzed by CYP1A1 involving generation of potentially toxic metabolites. J Pharmacol Exp Ther 2017;363:12\u201319. https:\/\/doi.org\/10.1124\/JPET.117.243246\/-\/DC1.","journal-title":"J Pharmacol Exp Ther"},{"key":"8873_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/00498254.2013.848310","volume":"44","author":"M Stiborov\u00e1","year":"2014","unstructured":"Stiborov\u00e1 M, Frei E, Arlt VM et al. Knockout and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica. 2014;44:135\u2013145. https:\/\/doi.org\/10.3109\/00498254.2013.848310.","journal-title":"Xenobiotica."},{"key":"8873_CR36","doi-asserted-by":"publisher","first-page":"6103","DOI":"10.1038\/s41598-018-24213-5","volume":"8","author":"C Manzella","year":"2018","unstructured":"Manzella C, Singhal M, Alrefai WA et al. Serotonin is an endogenous regulator of intestinal CYP1A1 via AhR. Sci Rep. 2018;8:6103. https:\/\/doi.org\/10.1038\/s41598-018-24213-5.","journal-title":"Sci Rep."},{"key":"8873_CR37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bcp.2019.01.001","volume":"161","author":"M Salaga","year":"2019","unstructured":"Salaga M, Binienda A, Piscitelli F et al. Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. Biochem Pharmacol. 2019;161:37\u201351. https:\/\/doi.org\/10.1016\/j.bcp.2019.01.001.","journal-title":"Biochem Pharmacol."},{"key":"8873_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0011-393X(98)85095-9","volume":"59","author":"U Klotz","year":"1998","unstructured":"Klotz U, Hoensch H, Sch\u00fctz T et al. Expression of intestinal drug-metabolizing enzymes in patients with chronic inflammatory bowel disease. Curr Ther Res. 1998;59:556\u2013563. https:\/\/doi.org\/10.1016\/S0011-393X(98)85095-9.","journal-title":"Curr Ther Res."},{"key":"8873_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2019.12.003","volume":"10","author":"C Lv","year":"2020","unstructured":"Lv C, Huang L. Xenobiotic receptors in mediating the effect of sepsis on drug metabolism. Acta Pharm Sin B. 2020;10:33\u201341. https:\/\/doi.org\/10.1016\/j.apsb.2019.12.003.","journal-title":"Acta Pharm Sin B."},{"key":"8873_CR40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/01.CCM.0000109453.57709.E2","volume":"32","author":"JH Crawford","year":"2004","unstructured":"Crawford JH, Yang S, Zhou M et al. Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis. Crit Care Med. 2004;32:502\u2013508. https:\/\/doi.org\/10.1097\/01.CCM.0000109453.57709.E2.","journal-title":"Crit Care Med."},{"key":"8873_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.toxlet.2017.03.028","volume":"275","author":"H Cui","year":"2017","unstructured":"Cui H, Gu X, Chen J et al. Pregnane X receptor regulates the AhR\/Cyp1A1 pathway and protects liver cells from benzo-[\u03b1]-pyrene-induced DNA damage. Toxicol Lett. 2017;275:67\u201376. https:\/\/doi.org\/10.1016\/j.toxlet.2017.03.028.","journal-title":"Toxicol Lett."},{"key":"8873_CR42","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1002\/ptr.5942","volume":"31","author":"VK Manda","year":"2017","unstructured":"Manda VK, Avula B, Dale OR et al. PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids. Phytother Res. 2017;31:1935\u20131945. https:\/\/doi.org\/10.1002\/ptr.5942.","journal-title":"Phytother Res."},{"key":"8873_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/J.TIPS.2012.03.003","volume":"33","author":"J Cheng","year":"2012","unstructured":"Cheng J, Shah YM, Gonzalez FJ. Pregnane X receptor as a target for treatment of inflammatory bowel disorders. Trends Pharmacol Sci. 2012;33:323. https:\/\/doi.org\/10.1016\/J.TIPS.2012.03.003.","journal-title":"Trends Pharmacol Sci."},{"key":"8873_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0300-483X(99)00200-0","volume":"144","author":"O Pelkonen","year":"2000","unstructured":"Pelkonen O, Rautio A, Raunio H et al. CYP2A6: a human coumarin 7-hydroxylase. Toxicology. 2000;144:139\u2013147. https:\/\/doi.org\/10.1016\/S0300-483X(99)00200-0.","journal-title":"Toxicology."},{"key":"8873_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1515\/dmdi-2012-0001","volume":"27","author":"H Raunio","year":"2012","unstructured":"Raunio H, Rahnasto-Rilla M. CYP2A6: genetics, structure, regulation, and function. Drug Metabol Drug Interact. 2012;27:73\u201388. https:\/\/doi.org\/10.1515\/dmdi-2012-0001.","journal-title":"Drug Metabol Drug Interact."},{"key":"8873_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312791","author":"A Grangeon","year":"2021","unstructured":"Grangeon A, Clermont V, Barama A et al. Determination of CYP450 expression levels in the human small intestine by mass spectrometry-based targeted proteomics. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms222312791.","journal-title":"Int J Mol Sci."},{"key":"8873_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911627","author":"S Satka","year":"2022","unstructured":"Satka S, Frybortova V, Zapletalova I et al. Effect of DSS-induced ulcerative colitis and butyrate on the cytochrome P450 2A5: contribution of the microbiome. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911627.","journal-title":"Int J Mol Sci."},{"key":"8873_CR48","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1530-0277.2011.01466.x","volume":"35","author":"G Swanson","year":"2011","unstructured":"Swanson G, Forsyth CB, Tang Y et al. Role of intestinal circadian genes in alcohol-induced gut leakiness. Alcohol Clin Exp Res. 2011;35:1305\u20131314. https:\/\/doi.org\/10.1111\/j.1530-0277.2011.01466.x.","journal-title":"Alcohol Clin Exp Res."},{"key":"8873_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1479-5876-9-129","volume":"9","author":"SE Lakhan","year":"2011","unstructured":"Lakhan SE, Kirchgessner A. Anti-inflammatory effects of nicotine in obesity and ulcerative colitis. J Transl Med. 2011;9:129. https:\/\/doi.org\/10.1186\/1479-5876-9-129.","journal-title":"J Transl Med."},{"key":"8873_CR50","first-page":"87","volume":"13","author":"GRDZS Altarescu","year":"2011","unstructured":"Altarescu GRDZS. Relationship between CYP2A6 genetic polymorphism, as a marker of nicotine metabolism, and ulcerative colitis. Isr Med Assoc J. 2011;13:87\u201390.","journal-title":"Isr Med Assoc J."},{"key":"8873_CR51","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/jpet.115.228205","volume":"356","author":"M Salaga","year":"2016","unstructured":"Salaga M, Blomster LV, Piechota-Pola\u0144czyk A et al. Encenicline, an \u03b17 nicotinic acetylcholine receptor partial agonist, reduces immune cell infiltration in the colon and improves experimental colitis in mice. J Pharmacol Exp Ther. 2016;356:157\u2013169. https:\/\/doi.org\/10.1124\/jpet.115.228205.","journal-title":"J Pharmacol Exp Ther."},{"key":"8873_CR52","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1124\/dmd.31.11.1346","volume":"31","author":"QY Zhang","year":"2003","unstructured":"Zhang QY, Dunbar D, Kaminsky LS. Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab Dispos. 2003;31:1346\u20131351. https:\/\/doi.org\/10.1124\/dmd.31.11.1346.","journal-title":"Drug Metab Dispos."},{"key":"8873_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-5-4","volume":"5","author":"I Bergheim","year":"2005","unstructured":"Bergheim I, Bode C, Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol. 2005;5:4. https:\/\/doi.org\/10.1186\/1472-6904-5-4.","journal-title":"BMC Clin Pharmacol."},{"key":"8873_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev.pharmtox.44.101802.121704","volume":"44","author":"AA Caro","year":"2004","unstructured":"Caro AA, Cederbaum AI. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu Rev Pharmacol Toxicol. 2004;44:27\u201342. https:\/\/doi.org\/10.1146\/annurev.pharmtox.44.101802.121704.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"8873_CR55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-7216-0693-4.50010-4","volume-title":"Haddad and Winchester\u2019s clinical management of poisoning and drug overdose","author":"MW Shannon","year":"2007","unstructured":"Shannon MW. Chapter 5\u2014drug interactions. In: Shannon MW, Borron SW, Burns MJ, eds. 4th edn. W.B Saunders; 2007; 97\u2013104. https:\/\/doi.org\/10.1016\/B978-0-7216-0693-4.50010-4.","edition":"4"},{"key":"8873_CR56","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/ecco-jcc\/jjw179","volume":"11","author":"YP Ding","year":"2017","unstructured":"Ding YP, Ladeiro Y, Morilla I et al. Integrative network-based analysis of colonic detoxification gene expression in ulcerative colitis according to smoking status. J Crohns Colitis. 2017;11:474\u2013484. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw179.","journal-title":"J Crohns Colitis."},{"key":"8873_CR57","doi-asserted-by":"publisher","first-page":"G185","DOI":"10.1152\/ajpgi.00354.2012","volume":"305","author":"CB Forsyth","year":"2013","unstructured":"Forsyth CB, Voigt RM, Shaikh M et al. Role for intestinal CYP2E1 in alcohol-induced circadian gene-mediated intestinal hyperpermeability. Am J Physiol Gastrointest Liver Physiol. 2013;305:G185\u2013G195. https:\/\/doi.org\/10.1152\/ajpgi.00354.2012.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"8873_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218368","author":"A Binienda","year":"2020","unstructured":"Binienda A, Twardowska A, Makaro A et al. Dietary carbohydrates and lipids in the pathogenesis of leaky gut syndrome: an overview. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21218368.","journal-title":"Int J Mol Sci."},{"key":"8873_CR59","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.crohns.2014.01.025","volume":"8","author":"M Salaga","year":"2014","unstructured":"Salaga M, Mokrowiecka A, Zakrzewski PK et al. Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). J Crohns Colitis. 2014;8:998\u20131009. https:\/\/doi.org\/10.1016\/j.crohns.2014.01.025.","journal-title":"J Crohns Colitis."},{"key":"8873_CR60","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1124\/JPET.116.232553","volume":"357","author":"VJ Walker","year":"2016","unstructured":"Walker VJ, Griffin AP, Hammar DK et al. Metabolism of anandamide by human cytochrome P450 2J2 in the reconstituted system and human intestinal microsomes. J Pharmacol Exp Ther. 2016;357:537. https:\/\/doi.org\/10.1124\/JPET.116.232553.","journal-title":"J Pharmacol Exp Ther."},{"key":"8873_CR61","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0075107","author":"J Bystrom","year":"2013","unstructured":"Bystrom J, Thomson SJ, Johansson J et al. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn\u2019s disease? PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0075107.","journal-title":"PLoS ONE."},{"key":"8873_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/J.PHARMTHERA.2014.05.011","volume":"144","author":"P Shahabi","year":"2014","unstructured":"Shahabi P, Siest G, Meyer UA et al. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol Ther. 2014;144:134\u2013161. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2014.05.011.","journal-title":"Pharmacol Ther."},{"key":"8873_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bbrc.2016.07.066","volume":"478","author":"Z Zou","year":"2016","unstructured":"Zou Z, Zuo D, Yang J et al. The ANXA1 released from intestinal epithelial cells alleviate DSS-induced colitis by improving NKG2A expression of Natural Killer cells. Biochem Biophys Res Commun. 2016;478:213\u2013220. https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.066.","journal-title":"Biochem Biophys Res Commun."},{"key":"8873_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007.","journal-title":"Pharmacol Ther."},{"key":"8873_CR65","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004.","journal-title":"Clin Pharmacokinet."},{"key":"8873_CR66","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMra032424","volume":"352","author":"GR Wilkinson","year":"2005","unstructured":"Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:2211\u20132221. https:\/\/doi.org\/10.1056\/NEJMra032424.","journal-title":"N Engl J Med."},{"key":"8873_CR67","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.apsb.2016.07.012","volume":"6","author":"F Xie","year":"2016","unstructured":"Xie F, Ding X, Zhang QY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B. 2016;6:374\u2013383. https:\/\/doi.org\/10.1016\/j.apsb.2016.07.012.","journal-title":"Acta Pharm Sin B."},{"key":"8873_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0009-9236(96)90022-3","volume":"59","author":"CC Lang","year":"1996","unstructured":"Lang CC, Brown RM, Kinirons MT et al. Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clin Pharmacol Ther. 1996;59:41\u201346. https:\/\/doi.org\/10.1016\/S0009-9236(96)90022-3.","journal-title":"Clin Pharmacol Ther."},{"key":"8873_CR69","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1146\/ANNUREV-NUTR-071813-105747\/CITE\/REFWORKS","volume":"34","author":"D Bishop-Bailey","year":"2014","unstructured":"Bishop-Bailey D, Thomson S, Askari A et al. Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism. Annu Rev Nutr. 2014;34:261\u2013279. https:\/\/doi.org\/10.1146\/ANNUREV-NUTR-071813-105747\/CITE\/REFWORKS.","journal-title":"Annu Rev Nutr."},{"key":"8873_CR70","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1210\/JC.2004-0966","volume":"90","author":"RP Gupta","year":"2005","unstructured":"Gupta RP, He YA, Patrick KS et al. CYP3A4 Is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab. 2005;90:1210\u20131219. https:\/\/doi.org\/10.1210\/JC.2004-0966.","journal-title":"J Clin Endocrinol Metab."},{"key":"8873_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/nu11102325","author":"D Cardoso-Silva","year":"2019","unstructured":"Cardoso-Silva D, Delbue D, Itzlinger A et al. Intestinal barrier function in gluten-related disorders. Nutrients. 2019. https:\/\/doi.org\/10.3390\/nu11102325.","journal-title":"Nutrients."},{"key":"8873_CR72","doi-asserted-by":"publisher","first-page":"34086","DOI":"10.1136\/BMJOPEN-2019-034086","volume":"10","author":"ML Chretien","year":"2020","unstructured":"Chretien ML, Bailey DG, Asher L et al. Original research: Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study. BMJ Open. 2020;10:34086. https:\/\/doi.org\/10.1136\/BMJOPEN-2019-034086.","journal-title":"BMJ Open."},{"key":"8873_CR73","doi-asserted-by":"publisher","first-page":"41690","DOI":"10.1074\/JBC.M105117200","volume":"276","author":"M Zhang","year":"2001","unstructured":"Zhang M, Chiang JYL. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem. 2001;276:41690\u201341699. https:\/\/doi.org\/10.1074\/JBC.M105117200.","journal-title":"J Biol Chem."},{"key":"8873_CR74","doi-asserted-by":"publisher","first-page":"1021924","DOI":"10.3389\/fimmu.2022.1021924","volume":"13","author":"N Calzadilla","year":"2022","unstructured":"Calzadilla N, Comiskey SM, Dudeja PK et al. Bile acids as inflammatory mediators and modulators of intestinal permeability. Front Immunol. 2022;13:1021924. https:\/\/doi.org\/10.3389\/fimmu.2022.1021924.","journal-title":"Front Immunol."},{"key":"8873_CR75","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1194\/jlr.M700330-JLR200","volume":"48","author":"I Kim","year":"2007","unstructured":"Kim I, Ahn SH, Inagaki T et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J Lipid Res. 2007;48:2664\u20132672. https:\/\/doi.org\/10.1194\/jlr.M700330-JLR200.","journal-title":"J Lipid Res."},{"key":"8873_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120055","volume":"10","author":"J Chai","year":"2015","unstructured":"Chai J, Feng X, Zhang L et al. Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstruction. PLoS ONE. 2015;10:e0120055. https:\/\/doi.org\/10.1371\/journal.pone.0120055.","journal-title":"PLoS ONE."},{"key":"8873_CR77","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/J.1440-1746.2011.06748.X","volume":"26","author":"G Kolouchova","year":"2011","unstructured":"Kolouchova G, Brcakova E, Hirsova P et al. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. J Gastroenterol Hepatol. 2011;26:1544\u20131551. https:\/\/doi.org\/10.1111\/J.1440-1746.2011.06748.X.","journal-title":"J Gastroenterol Hepatol."},{"key":"8873_CR78","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-4614-4711-5_8","volume":"763","author":"NP Lee","year":"2012","unstructured":"Lee NP. The blood-biliary barrier, tight junctions and human liver diseases. Adv Exp Med Biol. 2012;763:171\u2013185. https:\/\/doi.org\/10.1007\/978-1-4614-4711-5_8.","journal-title":"Adv Exp Med Biol."},{"key":"8873_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/S00795-003-0220-5","volume":"36","author":"T Kojima","year":"2003","unstructured":"Kojima T, Yamamoto T, Murata M et al. Regulation of the blood-biliary barrier: interaction between gap and tight junctions in hepatocytes. Med Electron Microsc. 2003;36:157\u2013164. https:\/\/doi.org\/10.1007\/S00795-003-0220-5.","journal-title":"Med Electron Microsc."},{"key":"8873_CR80","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1089\/ars.2011.3893","volume":"15","author":"CE Overgaard","year":"2011","unstructured":"Overgaard CE, Daugherty BL, Mitchell LA et al. Claudins: control of barrier function and regulation in response to oxidant stress. Antioxid Redox Signal. 2011;15:1179\u20131193. https:\/\/doi.org\/10.1089\/ars.2011.3893.","journal-title":"Antioxid Redox Signal."},{"key":"8873_CR81","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1242\/DEV.02706","volume":"134","author":"RE Hernandez","year":"2007","unstructured":"Hernandez RE, Putzke AP, Myers JP et al. Cyp26 enzymes generate the retinoic acid response pattern necessary for hindbrain development. Development. 2007;134:177. https:\/\/doi.org\/10.1242\/DEV.02706.","journal-title":"Development."},{"key":"8873_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/NRM3932","volume":"16","author":"TJ Cunningham","year":"2015","unstructured":"Cunningham TJ, Duester G. Mechanisms of retinoic acid signalling and its roles in organ and limb development. Nat Rev Mol Cell Biol. 2015;16:110. https:\/\/doi.org\/10.1038\/NRM3932.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"8873_CR83","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/AJMG.A.37804","volume":"170","author":"JEV Morton","year":"2016","unstructured":"Morton JEV, Frentz S, Morgan T et al. Biallelic mutations in CYP26B1: a differential diagnosis for Pfeiffer and Antley-Bixler syndromes. Am J Med Genet A. 2016;170:2706\u20132710. https:\/\/doi.org\/10.1002\/AJMG.A.37804.","journal-title":"Am J Med Genet A."},{"key":"8873_CR84","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1002\/AJMG.A.62387","volume":"185","author":"K Grand","year":"2021","unstructured":"Grand K, Skraban CM, Cohen JL et al. Nonlethal presentations of CYP26B1-related skeletal anomalies and multiple synostoses syndrome. Am J Med Genet A. 2021;185:2766\u20132775. https:\/\/doi.org\/10.1002\/AJMG.A.62387.","journal-title":"Am J Med Genet A."},{"key":"8873_CR85","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425250903032681","volume":"5","author":"JE Thatcher","year":"2009","unstructured":"Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol. 2009;5:875. https:\/\/doi.org\/10.1517\/17425250903032681.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"8873_CR86","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1242\/DEV.124.2.313","volume":"124","author":"P Kastner","year":"1997","unstructured":"Kastner P, Mark M, Ghyselinck N et al. Genetic evidence that the retinoid signal is transduced by heterodimeric RXR\/RAR functional units during mouse development. Development. 1997;124:313\u2013326. https:\/\/doi.org\/10.1242\/DEV.124.2.313.","journal-title":"Development."},{"key":"8873_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2003.12.005","volume":"328","author":"J Bastien","year":"2004","unstructured":"Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004;328:1\u201316. https:\/\/doi.org\/10.1016\/j.gene.2003.12.005.","journal-title":"Gene."},{"key":"8873_CR88","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0016089","author":"H Takeuchi","year":"2011","unstructured":"Takeuchi H, Yokota A, Ohoka Y et al. Cyp26b1 regulates retinoic acid-dependent signals in T cells and its expression is inhibited by transforming growth factor-\u03b2. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0016089.","journal-title":"PLoS ONE."},{"key":"8873_CR89","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1053\/J.GASTRO.2009.06.063","volume":"137","author":"SG Kang","year":"2009","unstructured":"Kang SG, Wang C, Matsumoto S et al. High and low vitamin A therapies induce distinct FoxP3+ T cell subsets and effectively control intestinal inflammation. Gastroenterology. 2009;137:1391. https:\/\/doi.org\/10.1053\/J.GASTRO.2009.06.063.","journal-title":"Gastroenterology."},{"key":"8873_CR90","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0072739","author":"K Fransen","year":"2013","unstructured":"Fransen K, Franz\u00e9n P, Magnuson A et al. Polymorphism in the retinoic acid metabolizing enzyme CYP26B1 and the development of Crohn\u2019s disease. PLoS ONE. 2013. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0072739.","journal-title":"PLoS ONE."},{"key":"8873_CR91","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2119\/molmed.2012.00094","volume":"18","author":"O Krivospitskaya","year":"2012","unstructured":"Krivospitskaya O, Elmabsout AA, Sundman E et al. A CYP26B1 polymorphism enhances retinoic acid catabolism and may aggravate atherosclerosis. Mol Med. 2012;18:712\u2013718. https:\/\/doi.org\/10.2119\/molmed.2012.00094.","journal-title":"Mol Med."},{"key":"8873_CR92","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/bs.apha.2015.04.006","volume":"74","author":"F Stevison","year":"2015","unstructured":"Stevison F, Jing J, Tripathy S et al. Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. Adv Pharmacol. 2015;74:373\u2013412. https:\/\/doi.org\/10.1016\/bs.apha.2015.04.006.","journal-title":"Adv Pharmacol."},{"key":"8873_CR93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1006\/excr.2000.5113","volume":"263","author":"H Kubota","year":"2001","unstructured":"Kubota H, Chiba H, Takakuwa Y et al. Retinoid X receptor alpha and retinoic acid receptor gamma mediate expression of genes encoding tight-junction proteins and barrier function in F9 cells during visceral endodermal differentiation. Exp Cell Res. 2001;263:163\u2013172. https:\/\/doi.org\/10.1006\/excr.2000.5113.","journal-title":"Exp Cell Res."},{"key":"8873_CR94","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1021\/acs.jmedchem.5b01780","volume":"59","author":"P Diaz","year":"2016","unstructured":"Diaz P, Huang W, Keyari CM et al. Development and characterization of novel and selective inhibitors of cytochrome P450 CYP26A1, the human liver retinoic acid hydroxylase. J Med Chem. 2016;59:2579\u20132595. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01780.","journal-title":"J Med Chem."},{"key":"8873_CR95","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/J.1365-2265.2011.04261.X","volume":"76","author":"M Hewison","year":"2012","unstructured":"Hewison M. An update on vitamin D and human immunity. Clin Endocrinol (Oxf). 2012;76:315\u2013325. https:\/\/doi.org\/10.1111\/J.1365-2265.2011.04261.X.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"8873_CR96","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/jn\/130.11.2648","volume":"130","author":"MT Cantorna","year":"2000","unstructured":"Cantorna MT, Munsick C, Bemiss C et al. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648\u20132652. https:\/\/doi.org\/10.1093\/jn\/130.11.2648.","journal-title":"J Nutr."},{"key":"8873_CR97","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/JBMR.5650070208","volume":"7","author":"JM Lemire","year":"1992","unstructured":"Lemire JM, Adams JS. 1,25-Dihydroxyvitamin D3 inhibits the passive transfer of cellular immunity by a myelin basic protein-specific T cell clone. J Bone Miner Res. 1992;7:171\u2013177. https:\/\/doi.org\/10.1002\/JBMR.5650070208.","journal-title":"J Bone Miner Res."},{"key":"8873_CR98","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1172\/JCI115072","volume":"87","author":"JM Lemire","year":"1991","unstructured":"Lemire JM, Clay Archer D. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest. 1991;87:1103\u20131107. https:\/\/doi.org\/10.1172\/JCI115072.","journal-title":"J Clin Invest."},{"key":"8873_CR99","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/EJI.200425491","volume":"35","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Mahon BD, Froicu M et al. Calcium and 1\u03b1,25-dihydroxyvitamin D3 target the TNF-\u03b1 pathway to suppress experimental inflammatory bowel disease. Eur J Immunol. 2005;35:217\u2013224. https:\/\/doi.org\/10.1002\/EJI.200425491.","journal-title":"Eur J Immunol."},{"key":"8873_CR100","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5152\/tjg.2018.17828","volume":"30","author":"J Huang","year":"2019","unstructured":"Huang J, Chen T, Liu Y et al. How would serum 25(OH)D level change in patients with inflammatory bowel disease depending on intestinal mucosa vitamin D receptor (VDR) and vitamin D1-\u03b1 hydroxylase (CYP27B1)? Turk J Gastroenterol. 2019;30:132\u2013138. https:\/\/doi.org\/10.5152\/tjg.2018.17828.","journal-title":"Turk J Gastroenterol."},{"key":"8873_CR101","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01462-4","author":"R D\u2019Cunha","year":"2024","unstructured":"D\u2019Cunha R, Azam T, Kalabic J et al. Evaluation of the effect of risankizumab on the pharmacokinetics of cytochrome P450 substrates in patients with moderately to severely active ulcerative colitis or Crohn\u2019s disease. Clin Pharmacokinet. 2024. https:\/\/doi.org\/10.1007\/s40262-024-01462-4.","journal-title":"Clin Pharmacokinet"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08873-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08873-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08873-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T01:49:34Z","timestamp":1743904174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08873-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["8873"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08873-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}